Please login to the form below
HS
This page shows the latest HS news and features for those working in and with pharma, biotech and healthcare.
Novo Nordisk partners with Heartseed on heart failure cell therapy
HS-001, Heartseed’s lead asset, is an investigational cell therapy using purified cardiomyocytes derived from induced pluripotent stem cells (iPSC). ... However, Novo Nordisk has the rights to co-commercialise HS-001 with Heartseed in Japan, with equal
Latest news
-
ChemoCentryx surges on phase 3 vasculitis study
The comprehensive win also took analysts by surprise, particularly as a similar drug in development at German biotech InflaRx – IFX-1 – disappointed in a mid-stage trial in hidradenitis suppurativa (HS), ... Those include C3 glomerulopathy, a group
-
European Medicines Agency departs London ahead of Brexit
From 4 March the official address of the EMA will be the permanent unit at Domenico Scarlattilaan 6, 1083 HS Amsterdam, although meetings will be held at the Spark building.
-
PMEA 2018: celebrating excellence in improving patient outcomes
the stage for its patient support website regarding Hidradenitis suppurativa (HS), a long-term skin condition.
-
Lucid’s “spellbinding” performance prompts multiple wins at Communiqué 2018
in Professional Education Programmes for its two-year hidradenitis suppurativa (HS) campaign for AbbVie.
-
Lucid picks up rare disease and orphan drugs trophy at PMEA 2017
The agency’s ‘EIDON’ project for AbbVie developed a specialist network and increased the number of specialist centres to advance outcomes of patients with hidradenitis suppurativa (HS).
More from news
Approximately 1 fully matching, plus 13 partially matching documents found.
Latest Intelligence
-
Power to the patient: digital innovation supporting patients with chronic diseases
Notably, the recent award-winning AbbVie HS Online campaign (developed to support those seeking a diagnosis of, and living with, hidradenitis suppurativa) is an example of this continuous evolution in practice. ... To find out more about the
-
Case study: Revolutionising Management of Hidradenitis Suppurativa in Europe
With limited specialist expertise available, HS looked set to remain an ill-understood and under-treated disease. ... Define best practice for HS management; 3. Implement best practice and create a community movement.
More from intelligence
Approximately 0 fully matching, plus 2 partially matching documents found.
Latest from PMHub
-
Increasing patient randomisation rate by 200% for a Top 5 global pharma
Phase IIa Moderate to Severe Hidradenitis Suppurativa Case Study. A Top 5 pharma was looking to randomise 192 patients with moderate to severe HS at 60 sites across the USA, Canada
-
Lucid’s magic touch is recognised, winning both Communiqué Medical Education Consultancy of the Year and Communiqué Communications Consultancy of the Year 2018
Excellence in Professional Education Programmes for ‘Revolutionising management of hidradenitis suppurativa (HS) in Europe: Why? ... What? How?’ – a programme that has revolutionised the European HS community.
-
PMEA win for TVF Communications and AbbVie Healthcare!
development of ‘The Story of HS: A Patient Journey’. ... The Story of HS took an innovative approach to training in a new therapy area.
-
TVF Communications shortlisted for two awards at PMEA 2016!
For both target diseases, Hunter Syndrome(MPS II) and Hidradenitis Suppurativa (HS), a timely diagnosis is imperative, as the early symptoms are often mistaken for far more common and far less ... HS is also a complex disease, which requires close
-
TVF Communications shortlisted for the Writing Excellence award at Communique 2016
This training initiative involved launching both nurses and internal AbbVie stakeholders into the world of the typical Hidradenitis Suppurativa (HS) patient; in order to create a compelling story to support positive ... of improving the lives of HS
More from PMHub
Approximately 1 fully matching, plus 5 partially matching documents found.
Subscribe to our email news alerts
Featured jobs
- Country Manager, Healthcare Communications Agency, Germany
-
Highly competitive salary
- Sanofi halts recruitment for trials assessing MS treatment
- bluebird bio reveals plans to launch two gene therapies
- AstraZeneca and Daiichi Sankyo receive FDA approval for lung cancer drug
- ONS data reveals significant decrease in COVID-19 antibodies
- Bristol Myers Squibb and GentiBio in $1.9bn deal to develop IBD therapies
- UK government’s ‘science superpower’ ambitions to fail without clear plan, Lords committee warns
- WHO releases interim statement on COVID-19 vaccination for children and adolescents
- Novartis reports death of two patients treated with Zolgensma
- The impact of COVID-19 on the fight against AMR
- NHS bowel cancer checks reach record-high following death of Dame Deborah James
- Environment: where does the pharmaceutical industry stand?
- Moderna’s Omicron booster receives MHRA approval
- Sanofi halts recruitment for trials assessing MS treatment
- BeiGene announces positive phase 3 trial results for liver cancer treatment
- Amgen acquires ChemoCentryx in $3.7bn cash deal
- A creative awakening – how pharma is bringing innovation to the patient journey
- Superstar congresses and conferences will stay centre stage but now share the limelight with virtual and hybrid events
- AbbVie and Sosei Heptares collaborate in new agreement worth up to $1.2bn
PMHub
Origins Insights
Origins are part of the Resonant Group. Using novel research methodologies, we dig deeper to deliver authentic audience experiences that...
Latest intelligence
- Environment: where does the pharmaceutical industry stand?
- ...
- The communication challenge of helping he next generation to be healthier
- As the pressure on the health service increases the health of the next generation is vital for everyone. How do we show positive attitudes and change behaviour while future proofing...
- Are we losing sight of what the democratisation of healthcare really looks like?
- We have a core responsibility as healthcare communicators to consistently drive for better inclusion, engagement and compliance. What does the ‘democratisation of healthcare’ really look like?...
